References
- Drug approval package-Exparel (bupivacaine liposome) Injectable Suspension. [ cited 2017 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022496Orig1s000TOC.cfm
- Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures. Reg Anesth Pain Med. 2002;27:556–561.
- Barrington MJ, Watts SA, Gledhill SR, et al. Preliminary results of the Australasian regional anaesthesia collaboration: a prospective audit of more than 7000 peripheral nerve and plexus blocks for neurologic and other complications. Reg Anesth Pain Med. 2009;34:534–541.
- Barrington MJ, Kluger R. Ultrasound guidance reduces the risk of local anesthetic systemic toxicity following peripheral nerve blockade. Reg Anesth Pain Med. 2013;38:289–297.
- FDA: Label for Marcaine. [ cited 2016 Nov 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018692s015lbl.pdf
- Duh MS, Cremieux P, Audenrode MV, et al. Can social media data lead to earlier detection of drug-related adverse events? Pharmacoepidemiol Drug Saf. 2016;25:1425–1433.
- Exparel Seizure post op. [ cited 2016 Nov 21]. Available from: http://www.nurse-anesthesia.org/archive/index.php/t-17995.html
- Smith MP, Anchan RK. Exparel-Ized [abstract]. J Hosp Med. 2016;11:suppl 1. [cited 2017 Mar 31]. http://www.shmabstracts.com/abstract/exparel-ized/.
- FDA: Label for Exparel. [ cited 2016 Nov 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf
- FDA: exparel and LAST-Need for regulatory action. [ cited 2016 Nov 29]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm509478.htm
- FDA FAERS. [ cited 2016 Nov 21]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/
- Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf. 2015;14(2):325–334.
- Arabyat RM, Raisch DW, McKoy JM, et al. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system. Expert Opin Drug Saf. 2015;14(11):1653–1660.
- Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. Drugs - Real World Outcomes. 2016;3(2):145–154.
- Faich G, Morris J. Adverse reaction signaling and disproportionality analysis: an update. Drug Saf. 2012;46(6):708–714.
- Hou Y, Ye X, Wu G, et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf. 2014;13(7):853–857.
- Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19:3199–3209.
- Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–486.
- Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436.
- Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: editor, Karahoca A. Data mining applications in engineering and medicine. 2012 InTech. ISBN 978-953-51-0720-0
- Brinker AD, Lyndly J, Tonning J, et al. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA adverse event reporting system (FAERS) database. Drug Saf. 2013 Dec;36(12):1169–1178.
- Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24:743–749.
- Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States Food and Drug Administration’s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294. DOI:10.1007/s40264-014-0150-2
- Hoffman KB, Demakas AR, Dimbil M, et al. Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014;37(11):971–980. DOI:10.1007/s40264-014-0225-0
- Dullenkopf A, Borgeat A. Local anesthetics. Differences and similarities in the “-cains”. Anaesthesist. 2003 Apr;52(4):329–340.
- Skolnik A, Gan TJ. New formulations of bupivacaine for the treatment of postoperative pain: liposomal bupivacaine and SABER-Bupivacaine. Expert Opin Pharmacother. 2014;15(11):1535–1542.
- Chahar P, Cummings KC. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257–264.
- Hu D, Onel E, Singla N, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig. 2013;33:109–115.
- Kharitonov V. A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials. Postgrad Med. 2014;126(1):129–138.
- Burbridge M, Jaffe RA. Exparel®: A new local anesthetic with special safety concerns. Anesth Analg. 2015;121(4):1113–1114.
- Anderson MR, Wilson SH, Rosenblatt MA. Decision-making in orthopedic and regional anesthesiology: A case-based approach. Cambridge (UK): Cambridge University Press; 2015.
- Noviasky J, Pierce DP, Whalen K, et al. Bupivacaine liposomal versus bupivacaine: comparative review. Hosp Pharm. 2014;49(6):539–543. DOI:10.1310/hpj4906-539
- Exparel [package insert]. San Diego (CA): Pacira Pharmaceuticals, Inc; 2012 Jun.
- Hadley RM, Dine AP. Where is the evidence? A critical review of bias in the reporting of clinical data for exparel: a liposomal bupivacaine formulation. J Clinic Res Bioeth. 2014;5:189.
- Bagsby DT, Ireland PH, Meneghini RM. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty. 2014;29(8):1687-90..